Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sarepta Outlines A Fast Path Forward For Its DMD Gene Therapy

Executive Summary

Encouraging data testing the gene therapy in just three boys with Duchenne muscular dystrophy has investors jazzed. CEO Doug Ingram said the company will talk to FDA about how to advance the program. 

You may also be interested in...



Sarepta Secures $1.15bn From Roche In Ex-US DMD Gene Therapy Deal

Including upfront payments, half of development costs for SRP-9001, $1.7bn in milestone fees and royalties on sales outside the US, Sarepta pegs deal’s value at $10bn-plus.

Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets

Not every drug developer can go public, but biopharma IPOs are launching in multiple markets, including Moderna's prospective $500m US offering and Innovent's $421m Hong Kong IPO. Also, Sarepta prices a $500m FOPO and Omeros sells $210m in notes.

Sarepta Commits To Rapid, Thorough Pivotal Study For DMD Gene Therapy Based On Functional Improvements

The company presented encouraging data on functional assessments of four boys treated with a micro-dystrophin gene therapy at the World Muscle Society, furthering momentum around the program.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel